CTOs on the Move

StemoniX

www.stemonix.com

 
StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

StemoniX raised $14.4M on 02/28/2019

Similar Companies

Mango Materials

Mango Materials produces biodegradable plastics from waste biogas (methane) that are economically competitive with conventional, oil-based plastics. Mango Materials produces poly-hydroxyalkanoate (PHA) powder, a valuable biopolymer that is converted into a variety of ecofriendly, plastic products such as children’s toys, electronic casings, water bottles, and food packaging containers. Due to a rising preference for green products, demand for biodegradable and non petroleum-based plastics is growing rapidly. Mango Materials uses affordable methane gas and a process that competes favorably with petroleum-based plastics to produce low-cost, biodegradable plastics.

Notable Labs

Notable Labs is a translationally focused drug development company that uses a clinically validated, automated compound sensitivity platform to identify and advance novel therapeutic candidates to dramatically reduce the cost and time of the traditional drug development process.

Kaiser Inc

Kaiser Inc is a Manteca, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eastern Maine Medical Center Federal Credit Union aka EMMC FCU

Eastern Maine Medical Center Federal Credit Union aka EMMC FCU is a Bangor, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jasper Therapeutics

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.